The high prevalence of multiple sclerosis is expected to propel the growth of the multiple sclerosis therapeutics markets. According to data from (updated November 2018), the Multiple Sclerosis Trust, the prevalence of MS in England is around 90,500 or 164 per 100,000 and about 3,200 or 175 per 100,000 in Northern Ireland.
Multiple sclerosis (MS) is an inflammatory condition that can affect not only the central nervous system and the spinal cord but also affecting other parts of the body. It is a lifelong condition that can at times be mild, but it can at times be severe. Multiple sclerosis affects every part of the body, even to the extremities, but does tend to affect young people more than older people. Products in the multiple sclerosis therapeutics markets are designed to control and slow down inflammation and reducing symptoms.
Products in the multiple sclerosis therapeutics markets can be divided into two categories: one to treat the specific symptoms of multiple sclerosis, and one to relieve the overall fatigue and pain associated with the disease. Many people with MS suffer from a loss of balance, and this is one of the main symptoms. Multiple sclerosis drugs can be used to relieve the fatigue associated with the disease, and they often work well for patients who use them to treat the more severe symptoms.
Some MS drugs in the multiple sclerosis therapeutics markets are aimed at correcting the inflammation and at regulating the production of one protein, called interleukin. Daclizumab is a humanized monoclonal antibody that prevents the formation of high-affinity interleukin (IL)-2 receptor (IL-2R). It also restricts the initial steps of T-cell activation by blocking the trans-presentation of IL-2 by dendritic cells to antigen-specific T cells.
Other drugs in the multiple sclerosis therapeutics market include interferon beta drugs. Multiple sclerosis patients usually respond very well to interferon beta drugs. The drugs are administered in combination with other medications and therapies such as phototherapy, cortisone, and biologic therapy which can also have favorable results in some patients. Interferon beta drugs lessen the inflammation from the misfiring immune system. This in turn reduces the damage to the myelin sheaths that cover your nerves.
The multiple sclerosis therapeutics market is witnessing the R&D of new drugs. In July 2021, Immunic, Inc., a clinical-stage biopharmaceutical company, received the U.S. Food and Drug Administration clearance for its Investigational New Drug Application for a phase 3 clinical trial assessing the efficacy and safety of IMU-838, the company’s selective oral DHODH inhibitor, in patients with relapsing-remitting MS.